FDA Approves Expanded Use of Vertex's Casgevy CRISPR Gene Therapy for Sickle Cell Disease in Children as Young as 2

What's happening

The U.S. Food and Drug Administration approved expanded use of Casgevy (exagamglogene autotemcel) on July 1, 2026, lowering the eligible patient age from 12 years to 2 years for both sickle cell disease (SCD) with recurrent vaso-occlusive crises and transfusion-dependent beta thalassemia (TDT). The decision was announced by Vertex Pharmaceuticals on July 2, 2026, and reported by Reuters. Casgevy, co-developed by Vertex Pharmaceuticals (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP), holds the distinction of being the first approved genetic therapy indicated for children as young as 2 years for both conditions.

The FDA processed the expanded-use application through its Commissioner's National Priority Voucher program, granting approval 53 days after filing — a notably compressed regulatory timeline. Casgevy's original FDA approval for SCD was granted on December 8, 2023, at that time restricted to patients 12 years and older. The pediatric expansion now broadens the labeled indication to encompass a substantially younger patient population across both disease indications.

Why it matters for markets

The expanded approval adds approximately 5,500 U.S. children to the pool of patients who are now labeled candidates for Casgevy, representing a meaningful increase in the therapy's total addressable market beyond the adolescent and adult population covered under the original 2023 authorization. For Vertex Pharmaceuticals, which reported revenue of $12.22 billion and carries a market capitalization of approximately $126.40 billion, Casgevy represents a strategic diversification beyond its core cystic fibrosis franchise built around CFTR modulators such as Trikafta. Penetration of the pediatric SCD and TDT market could contribute an incremental commercial opportunity, though the one-time treatment model and complex administration process are factors that will shape the pace of uptake.

For CRISPR Therapeutics, the commercial stakes are proportionally more significant given the company's scale. CRSP reported revenue of $4.1 million and holds a market capitalization of approximately $5.48 billion, meaning Casgevy's commercial trajectory carries outsized weight relative to the company's current revenue base. The 53-day approval timeline via the FDA's Commissioner's National Priority Voucher program also signals a regulatory pathway that could be relevant for future gene therapy filings, both for this partnership and the broader sector. The expanded pediatric label reinforces Casgevy's position as the first CRISPR-based gene therapy to reach this age group for either indication.

Sectors and assets to watch

Vertex Pharmaceuticals (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) are the primary companies directly affected by this regulatory development, as co-developers and commercialization partners for Casgevy. Vertex, with its established rare-disease infrastructure and $12.22 billion revenue base, is positioned as the commercial lead, while CRSP's pipeline also includes allogeneic CAR-T programs and in vivo gene-editing candidates in oncology and autoimmune indications that could benefit from demonstrated regulatory momentum in the CRISPR space.

More broadly, the gene therapy and gene-editing sector will be watching this approval as a data point on the FDA's willingness to extend CRISPR-based therapies into younger pediatric populations and on the utility of the Commissioner's National Priority Voucher program as an accelerated review mechanism. Companies developing competing or complementary gene therapies for hemoglobinopathies and other rare pediatric diseases operate in a sector where regulatory precedents set by Casgevy's expanding label carry meaningful implications for clinical development strategies.

What to watch next

Key developments to monitor include the rate at which treatment centers qualify and scale to administer Casgevy to the newly eligible pediatric population, given the therapy's complex ex vivo manufacturing and administration requirements. Vertex's future quarterly disclosures will be the primary source of data on commercial uptake across both the existing 12-and-older population and the newly added 2-to-11 age cohort. Additionally, any further label expansions, outcomes data from pediatric patients treated under the new indication, and the potential use of the Commissioner's National Priority Voucher program for other pending gene therapy applications will be relevant signals for the trajectory of both Casgevy specifically and the CRISPR therapeutics sector more broadly.